Status:
COMPLETED
Efficacy and Safety of SEROQUEL Extended Release (XR) in Acute Schizophrenia
Lead Sponsor:
AstraZeneca
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The purpose of the study is to determine whether treatment with quetiapine XR (Seroquel XR) tablets for 3 weeks will improve their agitation when they have acute psychosis.
Eligibility Criteria
Inclusion
- Requirement for treatment of acute episode of schizophrenia (according to DSM-IV diagnostic criteria)
- PANSS total score of ³ 75
- CGI \> 4
Exclusion
- Any DSM-IV (Diagnostic and Statistical Manual of Mental Disorders 4th Edition) Axis I disorder not defined in the inclusion criteria
- Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others
- Substance or alcohol dependence at enrollment
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2010
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00954122
Start Date
September 1 2009
End Date
April 1 2010
Last Update
January 8 2013
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Johor Bahru, Johor Bahru, Malaysia
2
Research Site
Kuala Lumpur, Malaysia